Literature DB >> 3947880

Radioimmunolocalization and selection for surgery in recurrent colorectal cancer.

R H Begent, P A Keep, F Searle, A J Green, H D Mitchell, B E Jones, J Dent, J E Pendower, R A Parkins, K W Reynolds.   

Abstract

The value of radioimmunolocalization (RIL) of cancer depends on its performance in situations where the result determines the choice of management. A rise in serum carcinoembryonic antigen (CEA) values after apparently curative resection of colorectal cancer implies localized, resectable recurrence in some patients and widespread unresectable tumour in others. This study investigated the ability of RIL with radiolabelled antibody to CEA and a novel numerical method for analysis of results to determine the extent of disease in 31 patients with raised serum CEA but no physical signs of recurrence. Surgical exploration or conventional radiology later confirmed the presence of tumour in 94 per cent of sites which were positive by RIL. Negative RIL predicted the absence of disease in 53 per cent of patients. The investigation could discriminate between localized and disseminated disease and often performed better than conventional radiology. RIL appears useful in selection of patients for second look laparotomy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947880     DOI: 10.1002/bjs.1800730126

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies.

Authors:  H J Begent; K A Chester; K D Bagshawe; P A Keep; F Searle; J Boden; G M Barratt; A J Green; S J Riggs; D F Woodrow
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Accurate quantification of 131I distribution by gamma camera imaging.

Authors:  A J Green; S E Dewhurst; R H Begent; K D Bagshawe; S J Riggs
Journal:  Eur J Nucl Med       Date:  1990

3.  Symposium: The management of recurrent colorectal cancer.

Authors:  F F Attiyeh; H Ellis; M Killingback; G D Oates; P F Schofield; H J Staab; G Steele; P H Sugarbaker
Journal:  Int J Colorectal Dis       Date:  1986-07       Impact factor: 2.571

4.  The localization of anti-tumour monoclonal antibodies in colorectal cancer.

Authors:  N C Armitage
Journal:  Ann R Coll Surg Engl       Date:  1986-11       Impact factor: 1.891

Review 5.  Imaging in targeted delivery of therapy to cancer.

Authors:  Gairin Dancey; Richard H Begent; Tim Meyer
Journal:  Target Oncol       Date:  2009-10-08       Impact factor: 4.493

6.  In vivo studies on the uptake of radiolabelled antibodies by colorectal and gastric carcinoma xenografts.

Authors:  F Macdonald; M C Crowson; W H Allum; P Life; J W Fielding
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.